Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
ESLA
#3526
Estrella Immunopharma, Inc. Common Stock
1.2
2
+0.83%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+0.83%
Variazione Mensile
+10.91%
Variazione di 6 mesi
+29.79%
Variazione Annuale
+25.77%
Chiusura Precedente
1.2
1
Open
1.2
2
Bid
Ask
Low
1.2
2
High
1.2
2
Volume
1
Mercati
Mercato Azionario Statunitense
Salute
ESLA
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
TTM
Key stats
Total common shares outstanding
5.85 M
2.33 M
35.2 M
—
Valuation ratios
Enterprise value
—
—
36.11 M
149.91 M
Price to earnings ratio
—
—
-4.07
-0.42
Price to sales ratio
—
—
7.93
—
Price to cash flow ratio
—
—
-1.86
-25.78
Price to book ratio
—
—
7.9
-12.16
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-0.01
-0.1
-1.64
-4.99
Return on equity %
0.25
0.44
-1.71
-1.98
Return on invested capital %
-2.2
-24.51
-557.25
361.44
Gross margin %
—
—
100
—
Operating margin %
—
—
-194.49
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
-194.53
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
8.42
0.05
24.65
1.28
Inventory turnover
—
—
—
—
Asset turnover
—
—
0.53
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-0.27
-0.24
-0.59
-0.11
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
0.41
0.01
0.15
0.14
Net current asset value per share
0.52
0.01
0.16
0.18
Tangible book value per share
-0.85
-0.22
0.14
-0.48
Working capital per share
0.46
-0.23
0.16
-0.63
Book value per share
-0.85
-0.52
0.14
-0.48
Notizie
Estrella riporta tasso di risposta completa del 100% in trial sul linfoma
Estrella reports 100% complete response rate in lymphoma trial
Estrella presenterà i dati della fase 1 sulla terapia cellulare mirata a CD19
Estrella to present phase 1 data on CD19-targeted cell therapy
Estrella Immunopharma riceve avviso dal Nasdaq per ritardo nell’assemblea annuale
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting
Estrella Immunopharma chiude un’offerta diretta registrata di 8 milioni di dollari
Estrella Immunopharma closes $8 million registered direct offering
Il titolo di Estrella Immunopharma crolla dopo l’annuncio di un’offerta di 8 milioni
Estrella Immunopharma stock falls after announcing $8 million offering
Estrella Immunopharma raccoglie 8 milioni di dollari tramite offerta registrata
Estrella Immunopharma raises $8 million through registered offering